Last reviewed · How we verify
Arsenic Trioxide Injectable Solution
Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation.
Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation. Used for Acute promyelocytic leukemia (APL), Relapsed or refractory APL.
At a glance
| Generic name | Arsenic Trioxide Injectable Solution |
|---|---|
| Also known as | Trisenox / Arscimed |
| Sponsor | Medsenic |
| Drug class | Arsenic compound; differentiation agent and apoptosis inducer |
| Target | PML-RARA fusion protein; mitochondrial apoptotic pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Arsenic trioxide targets the PML-RARA fusion protein characteristic of APL, causing its degradation and leading to differentiation of leukemic promyelocytes into mature granulocytes. It also triggers apoptosis through mitochondrial pathways and generation of reactive oxygen species. The drug has dual activity as both a differentiating agent and an apoptosis inducer, making it effective in APL and potentially other hematologic malignancies.
Approved indications
- Acute promyelocytic leukemia (APL)
- Relapsed or refractory APL
Common side effects
- Differentiation syndrome (APL differentiation syndrome)
- QT prolongation
- Peripheral neuropathy
- Hyperleukocytosis
- Hepatotoxicity
- Nausea and vomiting
Key clinical trials
- The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART (PHASE1)
- Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arsenic Trioxide Injectable Solution CI brief — competitive landscape report
- Arsenic Trioxide Injectable Solution updates RSS · CI watch RSS
- Medsenic portfolio CI